AI assistant
HIKMA Pharmaceuticals PLC — Director's Dealing 2020
Apr 16, 2020
4841_dirs_2020-04-16_3e401c77-df2b-47ca-a1fd-501d8256e02c.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
RNS Number : 9314J
Hikma Pharmaceuticals Plc
16 April 2020
Hikma Pharmaceuticals PLC
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Said Darwazah |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Chairman |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 36,438 |
| d) | Aggregated information | N/A |
| e) | Date of the transaction | 15 April 2020 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Mazen Darwazah
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Mazen Darwazah |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice Chairman |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 19,318 |
| d) | Aggregated information | N/A |
| e) | Date of the transaction | 15 April 2020 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Majda Labadi
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Majda Labadi |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 16,146 |
| d) | Aggregated information | N/A |
| e) | Date of the transaction | 15 April 2020 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Riad Mishlawi
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Riad Mishlawi |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 20,146 |
| d) | Aggregated information | N/A |
| e) | Date of the transaction | 15 April 2020 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Bassam Kanaan
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Bassam Kanaan |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C. |
| c) | Price(s) and volume(s) | Price(s): £22.82 Volume(s): 23,233 |
| d) | Aggregated information | Number of Shares: 23,233 Price: £530,177 |
| e) | Date of the transaction | 14 April 2020 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Khalid Nabilsi
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Khalid Nabilsi |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C. |
| c) | Price(s) and volume(s) | Price(s): £22.82 Volume(s): 23,751 |
| d) | Aggregated information | Number of Shares: 23,751 Price: £541,998 |
| e) | Date of the transaction | 14 April 2020 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Susan Ringdal
a)
Name
Susan Ringdal
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the exercise of nil-cost options granted on 17 May 2013 and 11 June 2014 under the 2007 LTIP and nil-cost options granted on 10 April 2015 under the 2014 EIP Elements B and C
c)
Price(s) and volume(s)
| Share Plan | Price | Volume |
| 2013 LTIP | £22.82 | 18,424 |
| 2014 LTIP | £22.82 | 11,774 |
| 2015 EIP B | £22.82 | 6,006 |
| 2015 EIP C | £22.82 | 6,006 |
d)
Aggregated information
Number of Shares: 42,210
Price: £963,232
e)
Date of the transaction
15 April 2020
f)
Place of the transaction
London Stock Exchange (XLON)
Brian Hoffmann
a)
Name
Brian Hoffmann
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the vesting of nil-cost options granted on 11 May 2016 and 13 April 2017 under the 2014 EIP Element B.
c)
Price(s) and volume(s)
| Share Plan | Price | Volume |
| 2016 EIP B | £22.34 | 8,230 |
| 2017 EIP B | £22.34 | 9,327 |
d)
Aggregated information
Number of Shares: 17,557
Price: £392,223
e)
Date of the transaction
16 April 2020
f)
Place of the transaction
London Stock Exchange (XLON)
| a) | Name | Brian Hoffmann |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Disposal of Shares. |
| c) | Price(s) and volume(s) | Price(s): £22.79 Volume(s): 2,219 |
| d) | Aggregated information | Number of Shares: 2,219 Price: £50,571 |
| e) | Date of the transaction | 14 April 2020 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Peter Speirs
Company Secretary, responsible for releasing this announcement
16 April 2020
+44 (0) 20 7399 2760
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHBSGDSUGBDGGL